The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 2 , Pages 459-465, February 2010

Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure

Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

Received 13 January 2009; received in revised form 1 July 2009; accepted 22 July 2009. published online 14 September 2009.

Objective

The implantation of autologous bone marrow–derived cells has been used for the treatment of ischemic diseases, but obvious interindividual differences were observed in the improvement of regional perfusion and cardiac function after treatment. We examined the angiogenic potency of bone marrow cells from patients with different clinical backgrounds.

Methods

Bone marrow cells were collected from 25 patients scheduled to undergo sternotomy for various surgical procedures. We examined the quality of bone marrow cells and investigated their angiogenic potency by using an ischemic limb model in mice with severe combined immunodeficiency.

Results

When compared with their control cohort, bone marrow cells from patients with advanced age, renal failure, or anemia had significantly less c-kit– and CD34-positive stem cells (P < .05) and showed significantly lower vascular endothelial growth factor production and colony-forming units in culture (P < .05). Furthermore, the implantation of bone marrow cells from patients with advanced age, renal failure, or anemia into the ischemic limbs of mice also resulted in significantly worse blood flow recovery and clinical score when compared with the implantation of bone marrow cells from their control cohorts (P < .05). However, the bone marrow cells from patients with diabetes and hypertension did not show significant impairment of angiogenic potency when compared with their control cohorts.

Conclusions

The quality and angiogenic potency of bone marrow cells differs among patients. Advanced age, renal failure, and anemia should be the risk factors related to poor angiogenic potency of bone marrow cells for the treatment of ischemic diseases.

CTSNet classification: 23, 33

Abbreviations and Acronyms: SCID mice, mice with severe combined immunodeficiency, VEGF, vascular endothelial growth factor

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosures: None.

 This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture.

PII: S0022-5223(09)01007-1

doi:10.1016/j.jtcvs.2009.07.053

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 2 , Pages 459-465, February 2010